Champions Oncology (CSBR) Net Income towards Common Stockholders (2010 - 2026)
Champions Oncology's (CSBR) quarterly Net Income towards Common Stockholders came in at -$426000.0 in Q3 2026, up 8.58% year-over-year from -$392324.1 in Q3 2025, and up 36.13% on a QoQ basis from -$667000.0 in Q2 2026.
Powered by 
Analysis
Champions Oncology (CSBR) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Champions Oncology (CSBR) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$426000.0 in Q3 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 8.58% year-over-year to -$426000.0 in Q3 2026; TTM through Jul 2026 was -$1.1 million, a 138.84% decrease from a year earlier, with the FY2026 full-year figure at -$1.2 million, down 124.99% from the prior year.
- Net Income towards Common Stockholders for Q3 2026 stood at -$426000.0, up from -$667000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $4.5 million in Q1 2025 and bottomed at -$2.6 million in Q3 2023.
- Historically, Net Income towards Common Stockholders has averaged -$477263.2 across 5 years, with a median of -$344000.0 in 2022.
- The widest annual swing landed in 2023, when Net Income towards Common Stockholders plunged 12843.75%; it then surged 277.67% in 2025.
- Year by year, Net Income towards Common Stockholders stood at -$16000.0 in 2022, then plunged by 12843.75% to -$2.1 million in 2023, then soared by 135.15% to $728000.0 in 2024, then slumped by 67.45% to $237000.0 in 2025, then plunged by 279.75% to -$426000.0 in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$426000.0 in Q3 2026, -$667000.0 in Q2 2026, and -$279000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 241.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 121.36 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 198.40 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | -760,000.00 |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | -13.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | -46.71 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | -426,000.00 |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | -4.28 Bn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | -2.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | -426,000.00 |
| Apr 30, 2026 | -667,000.00 |
| Jan 31, 2026 | -279,000.00 |
| Oct 31, 2025 | 237,000.00 |
| Jul 31, 2025 | -466,000.00 |
| Apr 30, 2025 | -1.84 Mn |
| Jan 31, 2025 | 4.50 Mn |
| Oct 31, 2024 | 728,000.00 |
| Jul 31, 2024 | 1.31 Mn |
| Apr 30, 2024 | -109,000.00 |
| Jan 31, 2024 | -2.53 Mn |
| Oct 31, 2023 | -2.07 Mn |
| Jul 31, 2023 | -2.57 Mn |
| Apr 30, 2023 | -2.56 Mn |
| Jan 31, 2023 | -2.44 Mn |
| Oct 31, 2022 | -16,000.00 |
| Jul 31, 2022 | -319,000.00 |
| Apr 30, 2022 | -344,000.00 |
| Jan 31, 2022 | 787,000.00 |
| Oct 31, 2021 | 277,000.00 |